Science
Neurotoxin biology,engineered for what's next.
Botulinum neurotoxins are among the most precise biological tools in medicine — and not all of them are biologically identical. Object Pharma is exploring how differentiated neurotoxin biology could open new therapeutic possibilities, beginning with mental health.
01
Targeted uptake
Botulinum neurotoxins bind with high specificity to presynaptic nerve terminals and are internalized into the neuron.
02
Intracellular action
The neurotoxin light chain acts on proteins of the vesicle-release machinery inside the nerve terminal.
03
Modulated signaling
Neurotransmitter release at the junction is reduced, altering the signal between nerve and muscle.
04
Recovery
Signaling recovers over time as nerve terminals restore release function — a profile that differs by serotype.
Botulinum neurotoxin serotype A
The most extensively characterized serotype, and the basis of the first approved therapeutic neurotoxin products.
Research-use material — not a clinical product
Serotype biology
Botulinum neurotoxins comprise multiple serotypes — A through G — with distinct receptors, substrates and kinetic profiles. This natural diversity is a foundation of Object Pharma's platform thinking.
Differentiated kinetics
Biological differences between neurotoxins may translate into different profiles of onset and duration. Object Pharma is investigating how these differences could be matched to different therapeutic questions.
Statements on this page describe class-level biology and published external research. They do not constitute clinical evidence for OP01 or any Object Pharma candidate.
